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Systemic chemotherapy for gastric cancer is often associated with treatment-related toxicity, which is particularly severe in patients
with a poor performance status. In this paper, we describe the first study to evaluate S-1 monotherapy as an option for advanced
gastric cancer patients who are not candidates for combination chemotherapy due to poor clinical condition. Fifty-two patients with
Eastern Cooperative Oncology Group (ECOG) performance scale 2–3, whose general condition had made use of combination
chemotherapy impossible, were enrolled. S-1 was administered to 30 patients as second- or third-line therapy. The initial dose of S-1
was 35mgm
 2, administered b.i.d for 14 days every 3 weeks. With a median follow-up period of 33 weeks, the median progression-
free survival, and overall survival were 11 weeks (95% CI, 8–14) and 33 weeks (95% CI, 19–47), respectively. The overall 1-year
survival rate was 29% by intent-to-treat analysis. The overall response rate was 12% (95% CI, 3–21), and the percentage of stable
disease was 35%, resulting in the disease control rate of 47% (95% CI, 32–60). Significant drug-related toxicity included grade 3
diarrhoea (14%), anorexia (14%), fatigue (10%), neutropenia (10%), and leucopenia (6%). In conclusion, this study indicated the
modest activity of S-1 in gastric cancer patients with poor performance status.
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Performance status is a widely accepted parameter that predicts
response to chemotherapy and survival, and it is associated with
many factors such as age, previous chemotherapy, and comorbi-
dity (Lavin et al, 1982; Janunger et al, 2001; Wilson et al, 2005). In
advanced gastric cancer, patients are likely to suffer from poor
general condition due to anorexia and weight loss, often as a
consequence of peritoneal carcinomatosis. These patients have
been excluded from clinical trials, and chemotherapeutic options
for them are quite limited (Cunningham et al, 1987; Hsu et al,
1997).
Combination chemotherapy is a standard approach in advanced
gastric cancer, with many combination regimens showing a
response rate of 35–45% for first-line treatment. However, these
regimens are inevitably accompanied by substantial toxicities,
which reduce their value as a palliative treatment. This toxicity is
particularly significant in patients whose performance status is
compromised. S-1 is a fourth-generation oral fluoropyrimidine
that was developed to mimic protracted continuous infusion of
5-fluorouracil (5-FU). In the phase II trials conducted in Japan, S-1
monotherapy demonstrated promising activity which was compar-
able to combination chemotherapy in advanced gastric cancer, and
it has been one of the preferred agents for gastric cancer (Sakata
et al, 1998; Sugimachi et al, 1999; Koizumi et al, 2000). Moreover,
it has a safety profile, which is favourable compared with other
oral fluoropyrimidines used in gastric cancer. In addition, single
agent 5-FU has been an option for patients with poor general
condition, and also for patients complicated with disseminated
intravascular coagulation (Chao et al, 2000).
Based on these observations, S-1 may be a substitute for the
conventional chemotherapy in patients with poor general condi-
tion. We conducted the first prospective study to evaluate the
feasibility of S-1 as an option for gastric cancer patients who were
not candidates for more intensive chemotherapy due to poor
clinical condition.
PATIENTS AND METHODS
Patient eligibility
This study was designed as a single-institutional phase II trial.
Patients with histologically proven metastatic and/or relapsed
gastric adenocarcinoma were considered eligible for the study
when they met all of the following criteria: aged X18; Eastern
Cooperative Oncology Group (ECOG) performance scale 2–3;
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sassessable disease with or without measurable lesion; either
chemotherapy-naı ¨ve or having completed chemotherapy due to
disease progression within 3 months before entry; and adequate
haematological, renal, and hepatic functions. The latter was
defined as neutrophil X1500ml
 1, platelet X75000ml
 1, serum
creatinine p1.5mgdl
 1, total bilirubin p1.25 (or 1.5)   upper
limit of normal (ULN), and serum transaminases p2.5 (or 5.0)  
ULN in the absence (or presence) of liver metastasis. Patients were
excluded from the study if they had concurrent cancer within the
past 3 years (excluding basal cell carcinoma of the skin or cervical
carcinoma in situ), active metastasis to central nervous system, or
uncontrolled significant comorbid conditions. After the protocol
was approved by the institutional review board, written informed
consent with ICH Guidelines was obtained from patients.
Treatment schedule
The starting dose of S-1 was 35mgm
 2 twice daily (b.i.d). S-1 was
administered within 1h after the morning and evening meals for
14 consecutive days, followed by a 7-day resting period. The S-1
dosage assigned to the patients was calculated based on body
surface area, which was different from the Japanese dosing system.
The planned dose intensity was 327mgm
 2week
 1. The schedule
was repeated until the occurrence of disease progression,
unacceptable toxicities, or patient’s refusal. In the absence of
evidence of disease progression, the patients were allowed to
continue S-1 treatment to the maximum 12 cycles. A dose
reduction of 10mgm
 2 a day was made if Xgrade 3 haematolo-
gical or non-haematological toxicity was shown in the previous
cycle. Dose re-escalation was not allowed. Patients who required
more than 4 weeks of rest for recovery from any toxicity other
than alopecia, nausea, vomiting, or anaemia, or who required dose
reduction of more than two steps (total 20mgm
 2 a day) were
withdrawn from the study.
Evaluation of response and toxicity
Weight loss, comorbidity, and performance status at presentation
were established by direct questioning of the patient during a
preliminary assessment by a physician at the first attendance for
S-1 treatment. Baseline evaluations of each patient included
complete medical history with physical examination, complete
blood count (CBC), serum chemistry, urine analysis, and electro-
cardiography. A radiological evaluation was completed within 3
weeks before treatment. Fibre-optic gastroduodenoscopy and
positron-emission tomography were planned to examine complete
response (CR) of all measurable lesions. During treatment, patients
were evaluated by a weekly CBC. A physical examination including
weight, performance status, and serum chemistry were performed
before each subsequent cycle. Radiological studies were repeated
every two cycles.
Treatment response was evaluated by spiral CT scan according
to the guidelines of the Response Evaluation Criteria in Solid
Tumors (RECIST) committee. The response was analysed accord-
ing to an intent-to-treat (ITT) analysis. A measurable lesion was
defined as 10mm in the longest dimension. If a patient was
documented as having a CR or a partial response (PR), the
response was confirmed at least 4 weeks after the first evidence of
response.
Progression-free survival (PFS) was defined as the time elapsed
from the start of treatment until disease progression or death of
any cause, and overall survival (OS) was defined as the start of
treatment to death. Time-to-treatment-failure was defined as the
time interval between treatment initiation and cessation due to any
reason. All patients were evaluated for toxicity from the time of
their first cycle. Toxicity was evaluated as a grade according to the
NCI-CTC (version 2.0).
Biostatistics
The primary aim of this study was to test the hypothesis that
1-year survival would improve by what degree compared to
historical controls. The study was designed to have an 80% power
to show an improvement in 1-year survival rate to 30% from
historical control of 15 with 5% type-I error, using two-sided
testing, and assuming exponential overall survival times. Accord-
ing to Minimax phase II design, a sample size of 48 patients was
required. Considering a 5% drop-out rate, 52 patients were needed
for this trial. The secondary aims included response rate in
patients according to RECIST criteria, safety, PFS, time-to-
treatment-failure, and OS. Time-dependent variables were ana-
lysed using the Kaplan–Meier method and compared using the
log–rank test. Multivariate analysis was performed using Cox’s
proportional hazard regression model. Exact 95% confidence
interval (CI) was provided for proportions.
RESULTS
Patient characteristics
A total of 52 patients were enrolled between August 2004 and July
2006. Baseline patient characteristics are provided in Table 1. All
patients were evaluable for survival. The median age was 61 years,
including 12 patients (23%) who were X70 years old. Twenty-four
patients (46%) had performance status of grade 3. Median value of
weight loss from the diagnosis of gastric cancer to S-1 start was
7% (range 5–23%) and 21 patients (40%) suffered more than 10%
weight loss. Twenty-six patients had comorbidity other than
gastric cancer. More than half of the patients received prior
first- or second-line palliative chemotherapy. Twenty-two patients
(42%) had no history of palliative chemotherapy. Site of metastasis
commonly included peritoneum (45%), abdominal lymph nodes
(33%), and stomach (33%).
Table 2 summarises the prior chemotherapy which our patients
received. Twenty-one patients (40%) received prior adjuvant
chemotherapy after curative resection. The median time elapsed
from documentation of disease progression (or relapse) of
previous regimen to S-1 treatment was 36 days (range 14–73).
The median number of cycles of previous chemotherapy was eight
(range 2–24) per patient.
Treatment outcomes
The median dose administered per day was 100mg (range 80–
130). A total of 233 treatment cycles (median 2.5, range 1–12) were
administered. Six patients (12%) completed the planned 12 cycles.
Four patients were subjected to dose reduction by one step, and
two patients were by two steps due to grade 3 adverse events. Total
31 cycles were delayed in 16 patients with the median delayed
duration of 1 week (range 1–4). The reason of delay was as follows:
non-haematological toxicity in 13 cycles; haematological toxicity
in 10 cycles; and the patients’ will in the remaining eight cycles.
Finally, the median dose intensity of all patients was
308mgm
 2week
 1 (range 163–327), which the relative dose
intensity was 94%. Eighteen patients (35%) were transferred to
the other chemotherapy regimens after disease progression was
documented.
Survival
At the time of analysis, all the patients finished S-1 treatment. With
the median follow-up period of 33 weeks (range 3–98), 46 patients
showed disease progression, and all but eight patients (85%)
expired. Median overall survival duration was 33 weeks (95% CI,
19–47), and the 1-year survival rate was 29%. Median PFS was 11
weeks (95% CI, 8–14) (Figure 1). Patients with measurable disease
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s(n¼30) demonstrated a median PFS of 10 weeks (95% CI, 2–17)
while patients with assessable, but non-measurable disease
(n¼22) had a median PFS of 19 weeks (95% CI, 5–33) (P¼0.12).
When the PFS was analysed with respect to prior chemo-
therapy, among patients who received S-1 as first-line treatment
the median PFS was 18 weeks (95% CI, 7–23), whereas second- or
third-line patients showed 8 weeks (95% CI, 1–15) (P¼0.07).
Median time-to-treatment-failure of all the patients was 9 weeks
(95% CI, 14–104).
When we compared the PFS profile according to clinical
parameters by multivariate analysis, patients’ age (465)
(P¼0.015), and previous exposure to chemotherapy (P¼0.018)
were the significant factors for poor PFS for measurable disease.
For non-measurable disease, no factor was found to be significant
for PFS. Severe weight loss (grade 42) (P¼0.008), male sex
(P¼0.02), previous exposure to chemotherapy (P¼0.012), and
prior gastrectomy (P¼0.03) were independent factors for poor
overall survival.
Response
Response to therapy was assessable in all but one patient, who
withdrew the consent after the first cycle (Table 3). The overall
response rate was 12% (95% CI, 3–21), and the percentage of
stable disease was 35%, resulting in the disease control rate of 47%
(95% CI, 32–60). Of 30 patients with measurable disease, three
patients achieved a PR, and one had a CR giving an overall
response rate of 13% by ITT analysis. For 22 patients with non-
measurable disease, two patients showed CR, and nine patients
showed non-progressive disease. All but eight patients stopped S-1
treatment because of disease progression. Forty-four patients had
PD involving progression of pre-existing lesions, while the
remaining patients (15%) showed new lesions: peritoneal seeding
(n¼3), lung (n¼2), brain (n¼1), liver (n¼1), and bile duct
(n¼1). When the response was analysed with respect to prior
chemotherapy, among patients who received S-1 as first-line
treatment there were five responses (23%), whereas 30 second- or
third-line patients showed only one CR without a PR (3%)
(P¼0.07). When the response was also analysed according to
performance status, in ECOG two patients there were three
responses (11%), and also in ECOG three patients, there were
three responses (13%).
Toxicity
Toxicity was assessable in all 52 patients (Table 4). There was one
case of sudden death during treatment of an 81-year old man with
a history of hypertension who received six courses of treatment.
There was no evidence of disease progression or toxicity in this
patient, but there occurred sudden cardiac death in the resting
period of cycle 6. Common significant drug-related toxicity
included grade 3 diarrhoea (14%), anorexia (14%), fatigue
(10%), neutropenia (10%), and leucopenia (6%). Two patients
developed febrile neutropenia (4%). Three patients suffered weight
loss of more than 10% during S-1 treatment. Seven hospitalisations
possibly related to treatment occurred in six patients (12%);
gastrointestinal toxicity (n¼6), and aspiration pneumonia accom-
panied with febrile neutropenia (n¼1).
DISCUSSION
To the best of our knowledge, this is the first prospective report on
S-1 treatment in gastric cancer patients with poor performance
status. Old age, poor performance status, comorbidity, and
significant weight loss are adverse prognostic factors for gastric
cancer (Andreyev et al, 1998; Trumper et al, 2006). Regimens of
cisplatin, doxorubicin, or etoposide are associated with severe
drug-related toxicity that could offset the potential clinical benefit.
Recently developed chemotherapy regimens including taxanes,
irinotecan, and oxaliplatin have better safety profiles compared
to the older regimens. However, the benefit of these new regimens
has not been evaluated in patients with poor performance
status because such patients are traditionally excluded from
clinical trials.
The definition of poor general condition differs among studies,
but the first chemotherapeutic consideration for poor general
condition was the ELF regimen (etoposide, 5-FU, leucovorin)
(Wilke et al, 1990). This regimen showed favourable compliance
for elderly patients or those with cardiac disease preventing
doxorubicin treatment, but 20% of patients suffered from grade
3–4 neutropenia and 7% from grade 3 diarrhoea. High-dose
5-FU with leucovorin (HDFL) showed promising efficacy in
patients with poor general condition of old age, performance
status, comorbidity, malnutrition, and cytopenia (Hsu et al, 1997).
However, this regimen was associated with considerable
non-haematologic toxicity of mucositis and vomiting, and high
HDFL-induced neurotoxicity cast another concern on its safety.
Table 1 Patient characteristics
Patient characteristics Number of patients (%)
Total enrolled 52
Evaluable 52
Median age (years) (range) 61 (36–81)
Male: Female 33:19
ECOG Performance status
2 28 (54)
3 24 (46)
Primary site
Cardia 7 (13)
Non-cardia 44 (85)
Unknown 1 (2)
Histological type
Well-moderate differentiated 14 (27)
Poorly differentiated 24 (46)
Signet ring cell 10 (19)
Others 4 (8)
Prior gastrectomy
Yes 33 (64)
No 19 (36)
Prior chemotherapy
a
Yes 30 (58)
No 22 (42)
Site of measurable lesion
Abdominal LN 17 (35)
Liver 10 (20)
Abdominal mass 9 (18)
Mediastinal LN 6 (12)
Cervical LN 4 (8)
Lung 3 (7)
Site of non-measurable lesion
Carcinomatosis 23 (29)
Stomach 20 (25)
Bowel 15 (19)
Bone 4 (5)
Others 18 (22)
Metastatic site per patient
1 12 (23)
2 21 (40)
X3 19 (37)
ECOG¼Eastern Cooperative Oncology Group; LN¼lymph node.
aAs a palliative
chemotherapy.
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sA recent report dealt with FOLFIRI regimen in poor performers
(Beretta et al, 2006). Its response rate was promising (40%), but
grade 3–4 neutropenia (17%) was forcing dose reduction. There-
fore, none of these regimens is widely accepted as the reference,
and there is a vital need for new regimens that procure dose
intensity without impeding safety.
S-1 has been shown to be safe in Korean patients. In the
previous phase II trial, patients tolerated the highest dose intensity
ever reported, and grade 4 toxicity was not reported (Jeung et al,
2007). Therefore, we hypothesised that S-1 could also be applied in
patients whose general condition is compromised. When designing
this trial, we adopted a 2-week schedule of S-1 instead of the
conventional 4-week schedule. It is based on the knowledge that:
(1) S-1-related adverse reactions commonly appear 2–3 weeks
after treatment starts (Nagashima et al, 2005); (2) a 2-week
schedule showed the possibility of mitigated toxicity and
prolonged the medication period (Kimura et al, 2003); (3) this
schedule showed feasibility in heavily pretreated metastatic
colorectal cancer (Jeung et al, 2006); and (4) recent phase I study
of 2-week S-1 schedule demonstrated an antitumour activity in
chemotherapy-refractory gastric cancer, with a similar pharmaco-
kinetic profile to the conventional schedule (Zhu et al, 2007).
Another concern in designing this trial was how to measure the
efficacy of S-1 in our patients, since few studies have concentrated
on this poor performance status population (Wilke et al, 1990;
Hsu et al, 1997; Jeung et al, 2007). Gastric cancer is mixed with
considerable non-measurable proportion, and it is higher in
Korean patients compared with Western populations. Peritoneal
metastasis or locoregional recurrence comprises approximately
50% of initial recurrence of gastric cancer, most of which cannot
be numerically assessed by conventional imaging (Yoo et al, 2000).
Therefore, we concentrated on 1-year survival rather than response
rate to measure the clinical benefit of S-1.
Performance status is an indicator of a patient’s global ability
and it correlates with survival time. Preoperative performance
status of ECOG 2–3 in non-curable gastric cancer patients is
associated with a 1-year survival rate of 17%, compared with 43%
for ECOG 0-1 patients (Maehara et al, 1993). In a prospective trial
of 5-FU and cisplatin, ECOG 2–3 patients showed a 1-year survival
of 30% (Rougier et al, 1994). Our study was designed to prove a
1-year survival of 30%, which is somewhat high considering
the patients’ general condition and proportion of prior exposure to
chemotherapy. Nevertheless, this survival rate is a currently
acceptable range expected from any new regimen aiming at
second- or third-line treatment for gastric cancer (Assersohn et al,
2004; Chun et al, 2004; Wilson et al, 2005; Horinaka et al, 2006).
We obtained a 1-year survival rate of 29% with a response rate
of 11%. This suggests an activity of S-1 in gastric cancer patients
even with poor performance status. Although direct comparison is
difficult, our result was comparable to other single-agent
Table 3 Evaluation of tumour response
Patients
(n)C R P R S D P D C D N E
RR
(%)
DCR
(%)
Overall (95% CI) 52 3 3 18 22 5 1 12 (3–21) 47 (32–60)
Measurable 30 1 3 9 16 1 — 13 43
Non-measurable 22 2 — 9 6 4 1 9 50
CD¼clinical deterioration; CI¼confidence interval; CR¼complete response;
DCR¼disease control rate; NE¼not evaluable; PD¼progressive disease;
PR¼partial response; RR¼response rate; SD¼stable disease.
Table 2 Summary of prior chemotherapy
Number of patients Dose intensity Treatment cycle
Total CR-PR SD PD Median (range) Median (range)
Adjuvant
Doxorubicin 13 1.00 (0.82–1.00) 12 (5–12)
Taxanes 6 1.00 (0.73–1,00) 6 (5–9)
Cisplatin 2 NA (0.84, 1.00)
a NA (8, 9)
a
First-line
Taxanes 19 5 10 4 1.00 (0.75–1.00) 6 (2–9)
Cisplatin (7irinotecan) 5 2 3 — 0.94 (0.56–1.00) 6 (5–10)
Capecitabine 2 2 — — NA (1.00, 0.93)
a NA (7, 9)
a
Irofulven 2 — 1 1 NA (1.00, 1.00)
a NA (2, 6)
a
Oxaliplatin 2 — 2 — NA (0.98, 0.85)
a NA (8, 10)
a
Second-line
Taxanes 7 2 3 2 0.93 (0.58–1.00) 5 (2–9)
Cisplatin (7irinotecan) 3 — 1 2 0.84 (0.49–0.89) 2 (2–6)
Capecitabine 2 — 2 — NA (0.94, 0.95)
a NA (4, 9)
a
CR¼complete response; PD¼progressive disease; PR¼partial response; SD¼stable disease.
aMedian value was not obtainable due to small patient number (N¼2).
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Figure 1 Survival analysis of all patients (N¼52).
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schemotherapy regimens in pretreated patients or poor performers
(Cascinu et al, 1998; Chun et al, 2004; Horinaka et al, 2006).
Moreover, there was no difference in response or treatment
compliance according to other poor prognostic factors such as age,
comorbidity, or performance status. However, it should be noted
that treatment duration and efficacy seems dependent on previous
treatment. As first-line treatment, the median treatment cycle was
four, and five patients (23%) completed 12 cycles. Five patients
(23%) showed an objective response, which was comparable to a
conventional phase II trial of S-1 (Jeung et al, 2007). In contrast,
S-1 in second- or third-line treatment showed only one response,
and the median treatment cycle was two. This implies that although
S-1 monotherapy has an activity in poor performance status, this
activity appears to be restricted to first-line chemotherapy. There is
currently inadequate evidence that S-1 monotherapy could be
successfully used for salvage treatment in pretreated cases.
Another point to consider is that we observed a different
toxicity profile than that reported in a previous phase II trial
(Jeung et al, 2007). Our patients suffered more haematologic and
non-haematologic toxicity, and the incidences of grade 3
neutropenia, diarrhoea, and anorexia were increased. It is no
wonder if we assume that poor performance status reflects the
global deterioration of the host-defense activity against the tumour
and treatment burden. Although we did not assess the quality of
life in this study, most patients (83%) did not suffer further weight
loss during the S-1 treatment, and two patients gained weight and
increasing appetite. Moreover, rare grade 4 toxicity and the lack of
toxicity-related death indicate that S-1 could be applied safely to
this clinical setting. However, our result also indicates that
scrupulous evaluation of the adverse reaction needs for these
patients is because of the more severe toxicity profile.
To conclude, our prospective study suggested that S-1
monotherapy is tolerable and has modest activity in gastric
cancer patients with poor performance status. Owing to the
natural history of gastric cancer, patients are particularly prone
to clinical deterioration after diagnosis or during treatment
course. Therefore, it is especially important to consider
these patients to improve the global treatment outcome of gastric
cancer.
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